BRIEF published on 11/06/2024 at 13:47, 14 days 20 hours ago Medincell: 2024 revenues on the rise and significant clinical progress Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
BRIEF published on 11/06/2024 at 13:47, 14 days 20 hours ago Medincell : Revenus 2024 à la hausse et avancée clinique significative Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 14 days 20 hours ago Inside Information / Other news releases Medincell achieves 25% increase in 2024 UZEDY® revenue outlook reaching $100M and key milestone in Olanzapine LAI Phase 3 clinical trials. Teva Pharmaceuticals shares Q3 results Revenue Clinical Trials Medincell Teva Pharmaceuticals UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 14 days 20 hours ago Informations privilégiées / Autres communiqués Medincell relève ses prévisions de revenus UZEDY® de 25% et franchit une étape majeure dans l'essai clinique de l'Olanzapine LAI. Tous les détails dans le communiqué de presse de Teva pour le troisième trimestre 2024 Revenus Essai Clinique Medincell Teva UZEDY
BRIEF published on 10/01/2024 at 15:47, 1 month 19 days ago Franchissement de seuil par Mirova dans MEDINCELL Capital Franchissement De Seuil Actions Medincell Mirova
BRIEF published on 10/01/2024 at 15:47, 1 month 19 days ago Threshold crossing by Mirova in MEDINCELL Capital Actions Threshold Crossing Medincell Mirova
PRESS RELEASE published on 10/01/2024 at 15:42, 1 month 19 days ago Franchissement de seuil Déclaration de franchissement de seuil par Mirova pour le compte de fonds gérés, détenant 7,07% du capital et 5,01% des droits de vote de MEDINCELL Acquisition Franchissement De Seuil AMF Medincell Mirova
BRIEF published on 09/24/2024 at 11:54, 1 month 26 days ago Teva et Medincell Présentent des Résultats Prometteurs sur l'Olanzapine LAI pour la Schizophrénie Schizophrénie Essai Clinique Medincell Teva Olanzapine LAI
BRIEF published on 09/24/2024 at 11:54, 1 month 26 days ago Teva and Medincell Present Promising Results on Olanzapine LAI for Schizophrenia Clinical Trial Schizophrenia Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/24/2024 at 11:53, 1 month 26 days ago Inside Information / Other news releases Teva and Medincell reveal positive efficacy, safety, and tolerability data from Phase 3 study on Olanzapine LAI for schizophrenia treatment, presenting at ECNP 2024 Schizophrenia Treatment Phase 3 Study Medincell Teva Olanzapine LAI
Published on 11/21/2024 at 09:00, 51 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 16 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 26 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 51 minutes ago Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 51 minutes ago Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates
Published on 11/21/2024 at 09:41, 10 minutes ago Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/21/2024 at 08:59, 51 minutes ago Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 51 minutes ago Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 36 minutes ago EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 06:58, 2 hours 53 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 53 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 53 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 43 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 31 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
